Dr. Phillip J. Koo, MD, discusses advanced tools such as multi-parametric MRI and PET/CT for prostate cancer imaging, and how they outperform traditional, previously available methods.
Read More
Robert Abouassaly, MD, argues that the DECIPHER marker is not an ideal test for predicting patient’s response to chemotherapy. He cites the inconclusiveness of trials and research and the cost inefficiency of this biomarker. Also, he explains that the DECIPHER test’s classification system is based on RNA expression profiles, and not meant for therapeutic guidance. This is a counter argument to Alan H. Bryce’s lecture, “The DECIPHER Marker Can Predict Chemotherapy.”
Read More
Dr. Alan H. Bryce, MD, discusses the newest advances and research in prostate cancer treatments that target androgen receptors, such as BET inhibitors and CYP17 inhibitors, as opposed to chemotherapeutic and radiopharmaceutical approaches.
Read More
Erik P. Castle, MD, explains approaches to improving ERAS for non-muscle invasive bladder cancer patients who have gone through radical cystectomy and other surgeries. He emphasized the benefits of administering Alvimopan in this process.
Read More
Dr. Michael S. Cookson, MD, MMHC, discusses the advantages of using MRI for the enhanced detection of prostate cancer, as opposed to traditional biopsy.
Read More
David C. Beyer, MD, reviews recent data regarding external beam radiation, brachytherapy, and androgen deprivation therapy (ADT) as it relates to radiation oncology and prostate cancer treatment.
Read More
Dr. Phillip J. Koo, MD, discusses the use of radiopharmaceuticals in prostate cancer treatment, as well as the area of theranostics. He goes into detail on the process of choosing these radiopharmaceuticals and trying to determine the best ones to use in various situations in regards to prostate cancer.
Read More
Dr. Ryan P. Terlecki, MD, FACS, discusses bladder neck contractures and the causes behind them, the possible sources of the symptoms, the outcomes of what has been done in the past, and what could potentially work in the future.
Read More
David C. Beyer, MD, argues that there is enough research from randomized trials and clinical studies for the urological community to consider high intensity focused ultrasound (HIFU) as a standard of care for treating prostate cancer patients.
Read More
Erik P. Castle, MD, argues that using high intensity focused ultrasound (HIFU) to treat prostate cancer, as the technology stands today, results in too many negative quality of life outcomes for patients. Therefore, HIFU is not ready to be a standard of care in urological practices.
Read More
Dr. Phillip J. Koo, MD, discusses the appropriate timing of radium 223 treatments in castration resistant prostate cancer patients, the best approaches to therapeutic layering, and the importance of recognizing bone metastasis when making these therapeutic decisions.
Read More
Alan H. Bryce, MD, argues that the urologic community should expand genetic testing in prostate cancer patients. With expansive, quality data, urologists will be able to better recognize aberrations in patients’ genes. Also, this would be a step closer to gaining FDA approved biomarkers for prostate cancer.
Read More
